Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol/Oncol 1998; 20: 315–318. Article CAS Google Scholar ...

Topotecan (Hycamtin ®) is a semisynthetic analogue of the alkaloid camptothecin that acts as a specific inhibitor of the nuclear enzyme topoisomerase-I (Herben et al, 1996). Inhibition of this ...

Topotecan was administered at the phase II recommended doses of 1 mg/m 2 iv on days 1 to 5, and UCN-01 at 70 mg/m 2 iv on day 1 of the first cycle, and 35 mg/m 2 iv on day 1 of subsequent cycles.

Two hundred seventy-three patients were randomly assigned (topotecan, n = 137; observation, n = 136), with a median age of 56 years. Stage at diagnosis was advanced in three fourths of patients (stage ...

Topotecan Medication Information Learn everything you need to know about Topotecan-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it.

Investigators randomly assigned 119 patients to IV topotecan (Hycamtin, GlaxoSmithKline) 2 mg/m 2 daily for 5 days or IV topotecan 0.75 mg/m 2 daily plus cyclophosphamide 250 mg/m 2 daily for 5 days.

Topotecan's time has passed. "Topotecan's time has passed. There is not a better schedule or dose scheme out there to try," Dr. Hoskins told Medscape Medical News.

Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity, according to a ...

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91): NICE response to consultee and ...

A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma.MINNEAPOLIS, Jan ...

Lurbinectedin superior to topotecan in platinum-resistant ovarian cancer Overall response rate (ORR), the primary endpoint together with safety, was 22% with lurbinectedin and 0% with topotecan.